Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Results indicated similar corticosterone levels but impaired memory performances and increased cerebral staining of thioflavine and of HO1 in the sham AD rats compared to the controls.
|
31796670 |
2020 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Transcripts of the transcription factor NFE2L2 and inducible HMOX1, were also increased in the AD-STG, and this corresponded to increased Nuclear factor erythroid 2-related factor (NRF-2) and total heme-oxygenase (HO) activity.
|
30068908 |
2018 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results indicated that KT can protect HT22 cells from glutamate-induced cell death by activating Nrf2 pathway and inducing expression of HO-1, suggesting KT might be a drug candidate for treatment of AD and other neurodegenerative disorders related to oxidative stress.
|
28900849 |
2018 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, HO-1 is a promising target for AD drug development.
|
30040734 |
2018 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, kinetin also increased the content of HO-1, and inhibited the distribution of Aβ<sub>1-42</sub> and the expressions of amyloidogenic proteins (APP, β-secretase, γ-secretase and Aβ<sub>1-42</sub>) in brain tissue of AD mice.
|
28867383 |
2017 |
Alzheimer's Disease
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
We evaluated DNA methylation status of HMOX1 at -374 promoter CpG site in blood samples from AD patients, patients with mild cognitive impairment (MCI), and control individuals using quantitative methylation-specific polymerase chain reaction.
|
27058954 |
2016 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The above data support the hypothesis that the dysregulation of HO-1/BVR-A system contributes to the early increase of oxidative stress in DS and provide potential mechanistic paths involved in the neurodegenerative process and AD development.
|
25391381 |
2015 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, the relationship between HO-1 and Alzheimer's disease remains unclear.
|
25114080 |
2015 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In "stressed" astroglia, HO-1 hyperactivity promotes mitochondrial iron sequestration and macroautophagy and may thereby contribute to the pathological iron deposition and bioenergetic failure documented in Alzheimer disease, Parkinson disease and certain neurodevelopmental conditions.
|
25761244 |
2015 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, targeted suppression of glial HO-1 hyperactivity may prove to be a rational and effective therapeutic intervention in AD and related neurodegenerative disorders.
|
25111043 |
2014 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Heme oxygenase-1 (HO-1), an inducible enzyme up-regulated in Alzheimer's disease, catabolises heme to biliverdin, Fe2+ and carbon monoxide (CO).
|
25501830 |
2014 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we determined whether 1) HMOX1 transfection fosters the accumulation of CA-like inclusions in cultured rat astroglia; 2) the HMOX1 transgene promotes CA formation in the brains of aging GFAP.HMOX1 mice; and 3) brain mitochondrial damage and CA biogenesis are augmented in persons with mild cognitive impairment (MCI), a harbinger of AD.
|
24440642 |
2014 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since 1950, many studies have revealed the role of HMOX1 in reducing the impact of oxidative stress in many types of diseases, such as Alzheimer's disease, heart disease, and the development of tumors.
|
23939757 |
2013 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
HO-1 protein levels were significantly increased in the hippocampus of AD subjects, whereas HO-2 protein levels were significantly decreased in both AD and MCI hippocampi.
|
22549002 |
2012 |
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Subjects carrying both the HO-1 (-413) TT genotype and the LXR-beta (intron 2) TT genotype (OR=2.63), LXR-beta (intron 5) AA genotype (OR=1.90), or LXR-beta (intron 7) TT genotype (OR=1.75) had a higher risk of developing AD than subjects without these risk genotypes.
|
18597895 |
2010 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Median serum levels of HO-1 did not differ significantly between AD patients and AD controls.
|
19785642 |
2010 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Further based upon these results, it was proposed that Abeta-induced heme oxygenase-1 can ensure cholesterol-oxidation to provide endogenous ligands for the sustained activation of neuronal LXR-α dependent epigenomic-pathway leading to neuronal death observed in Alzheimer's disease.
|
20927647 |
2010 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study failed to detect any association between the SNPs of the HMOX1 and HMOX2 genes and AD.
|
19246912 |
2009 |
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Subjects carrying both the HO-1 (-413) TT and the tau (5' of exon 1) AA genotypes had a more than 6.5-time higher risk of developing AD than subjects without these risk genotypes (OR = 6.65, 95% CI 1.12-39.29; p = 0.037).
|
18841019 |
2008 |
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Subjects carrying both the HO-1 (-413) TT and the tau (5' of exon 1) AA genotypes had a more than 6.5-time higher risk of developing AD than subjects without these risk genotypes (OR = 6.65, 95% CI 1.12-39.29; p = 0.037).
|
18841019 |
2008 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
LHGDN |
HOS activity of alpha(1)-antitrypsin may curtail HO-1-dependent derangement of cerebral iron homeostasis and account for diminished HO-1 expression in AD peripheral tissues.
|
16887359 |
2006 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
HOS activity of alpha(1)-antitrypsin may curtail HO-1-dependent derangement of cerebral iron homeostasis and account for diminished HO-1 expression in AD peripheral tissues.
|
16887359 |
2006 |
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Possible assessment for antioxidant capacity in Alzheimer's disease by measuring lymphocyte heme oxygenase-1 expression with real-time RT-PCR.
|
12480749 |
2002 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
CTD_human |
Amyloid precursor proteins inhibit heme oxygenase activity and augment neurotoxicity in Alzheimer's disease.
|
11144356 |
2000 |
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We recently observed that, paradoxically, HO-1 mRNA levels are markedly suppressed in peripheral lymphocytes of patients with early sporadic Alzheimer disease and may thus provide a useful biological marker of this condition.
|
11053673 |
2000 |